Carol Aghajanian, MD
Carol Aghajanian, MD
Chief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center
Verified email at mskcc.org - Homepage
Title
Cited by
Cited by
Year
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial …
C Aghajanian, SV Blank, BA Goff, PL Judson, MG Teneriello, A Husain, ...
Journal of clinical oncology 30 (17), 2039, 2012
12162012
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
K Moore, N Colombo, G Scambia, BG Kim, A Oaknin, M Friedlander, ...
New England Journal of Medicine 379 (26), 2495-2505, 2018
8062018
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
ML Hensley, R Maki, E Venkatraman, G Geller, M Lovegren, ...
Journal of Clinical Oncology 20 (12), 2824-2831, 2002
7032002
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ...
The Lancet 390 (10106), 1949-1961, 2017
6702017
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ...
Clinical cancer research 8 (8), 2505-2511, 2002
5662002
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
DS Chi, EL Eisenhauer, O Zivanovic, Y Sonoda, NR Abu-Rustum, ...
Gynecologic oncology 114 (1), 26-31, 2009
5212009
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center
NR Abu-Rustum, K Alektiar, A Iasonos, G Lev, Y Sonoda, C Aghajanian, ...
Gynecologic oncology 103 (2), 714-718, 2006
3652006
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum‐sensitive epithelial ovarian carcinoma
DS Chi, K McCaughty, JP Diaz, J Huh, S Schwabenbauer, AJ Hummer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2006
3462006
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer
EL Eisenhauer, NR Abu-Rustum, Y Sonoda, DA Levine, EA Poynor, ...
Gynecologic oncology 103 (3), 1083-1090, 2006
3342006
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
D Fennelly, C Aghajanian, F Shapiro, C O'flaherty, M McKenzie, ...
Journal of Clinical Oncology 15 (1), 187-192, 1997
2961997
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
MS Gordon, D Matei, C Aghajanian, UA Matulonis, M Brewer, GF Fleming, ...
Journal of Clinical Oncology 24 (26), 4324-4332, 2006
2772006
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
C Aghajanian, MW Sill, KM Darcy, B Greer, DS McMeekin, PG Rose, ...
Journal of clinical oncology 29 (16), 2259, 2011
2702011
Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient
A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ...
Cell 170 (5), 927-938. e20, 2017
2432017
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
2312015
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients
P Sabbatini, T Tsuji, L Ferran, E Ritter, C Sedrak, K Tuballes, ...
Clinical cancer research 18 (23), 6497-6508, 2012
2262012
Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ...
New England Journal of Medicine 381 (25), 2403-2415, 2019
2162019
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary …
RL Coleman, MW Sill, K Bell-McGuinn, C Aghajanian, HJ Gray, KS Tewari, ...
Gynecologic oncology 137 (3), 386-391, 2015
2072015
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
C Aghajanian, B Goff, LR Nycum, YV Wang, A Husain, SV Blank
Gynecologic oncology 139 (1), 10-16, 2015
2052015
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature
L Dos Santos, E Mok, A Iasonos, K Park, RA Soslow, C Aghajanian, ...
Gynecologic oncology 105 (2), 321-324, 2007
2032007
Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study
ML Hensley, N Ishill, R Soslow, J Larkin, N Abu-Rustum, P Sabbatini, ...
Gynecologic oncology 112 (3), 563-567, 2009
2012009
The system can't perform the operation now. Try again later.
Articles 1–20